JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, inclu…
Biotechnology
CN, Shanghai [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -100.00 | -0.69 | 0.00 | |
| Graham Fair Price | 100.00 | 9.30 | 0.00 | |
| PEG | 0.00 | 0.00 | 0.00 | |
| Price/Book | 100.00 | 0.50 | 0.00 | |
| Price/Cash Flow | -100.00 | -5.08 | 0.00 | |
| Prices/Earnings | -100.00 | -0.54 | 0.00 | |
| Price/Sales | 100.00 | 9.80 | 0.00 | |
| Price/FCF | -100.00 | -5.08 | 0.00 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 100.00 | 0.50 | 0.00 | |
| Operating Margin | -100.00 | -3.04 | 0.00 | |
| ROA | n.A. | -0.18 | n.A. | |
| ROE | n.A. | -0.23 | n.A. | |
| ROIC | n.A. | -0.13 | n.A. | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.00 | 0.00 | 0.00 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.00 | 0.00 | 0.00 | |
| EPS QOQ | 0.00 | 0.00 | 0.00 | |
| FCF QOQ | 0.00 | 0.00 | 0.00 | |
| Revenue QOQ | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Not Interpreted
Fundamentals
Leverage & Liquidity
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 73.29 | 100.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 23.82 | 100.00 | |
| Inventory Turnover | n.A. | 1.23 | n.A. | |
| Debt/Capitalization | 0.15 | 0.16 | 3.14 | |
| Quick Ratio | 3.70 | 3.91 | 5.58 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.00 | 4.09 | 100.00 | |
| Cash | 0.00 | 2.46 | 100.00 | |
| Capex | 0.00 | -0.01 | -100.00 | |
| Free Cash Flow | 0.00 | -0.40 | -100.00 | |
| Revenue | 0.00 | 0.21 | 100.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad